Evidence is graded on this page in four words: strong, moderate, emerging and limited. The evidence for a standard cancer treatment cannot be transferred to a different complementary therapy.
Standard options: strong. The ProtecT trial randomized 1,643 men with PSA-detected localized prostate cancer to active monitoring, prostatectomy or radiotherapy and followed them for a median of ten years. Deaths from prostate cancer were rare (17 in all) and did not differ significantly between the three groups; metastases and disease progression were more frequent in the monitoring group (Hamdy et al., N Engl J Med, 2016). That is the background against which every addition on this page has to be judged.
Immune therapy: emerging. The approved cellular immunotherapy sipuleucel-T prolonged median survival by about four months in metastatic castration-resistant prostate cancer (Kantoff et al., N Engl J Med, 2010). That product is a different therapy from the dendritic cell therapy given here, and ours has no trial of that kind.